There is no single “best” hormone replacement therapy. The most effective and safest option depends on your symptoms, age, health history, and whether you still have a uterus. What the evidence does make clear is that hormone therapy remains the most effective treatment for menopause symptoms, that starting it at the right time matters enormously, and that how hormones are delivered to your body changes the risk profile in meaningful ways.
Why Timing Matters More Than the Brand
The single most important factor in hormone therapy isn’t which product you choose. It’s when you start. Research consistently shows that women who begin hormone therapy before age 60, or within 10 years of menopause, see the greatest benefits and the fewest risks. Women in this window experience a 32% reduction in coronary heart disease events compared to those on placebo. They also see meaningful protection against bone loss.
Women who start hormone therapy after age 60 or more than 20 years past menopause see no cardiovascular benefit, and may face increased risk. This is known as the “timing hypothesis,” and it has fundamentally reshaped how clinicians approach prescribing. If you’re in your late 40s or 50s and experiencing hot flashes, night sweats, or other vasomotor symptoms, the evidence supports starting sooner rather than later.
Estrogen Plus Progesterone vs. Estrogen Alone
Which hormones you need depends on whether you have a uterus. Estrogen taken without a progestogen (a progesterone-like hormone) significantly raises the risk of endometrial cancer in women who haven’t had a hysterectomy. Adding progesterone effectively eliminates that risk. If you’ve had a hysterectomy, estrogen alone is typically the simpler and lower-risk option.
The type of progesterone also matters. Combined estradiol with micronized progesterone (a form that’s chemically identical to what your body produces) has been shown to carry a lower breast cancer risk than estradiol combined with synthetic progestins. This is one of the clearest findings in the hormone therapy literature, and it’s a key reason many clinicians now prefer micronized progesterone for women who need combination therapy.
Breast Cancer Risk in Context
Breast cancer risk is the concern that keeps many women from considering hormone therapy, so the actual numbers are worth understanding. A large meta-analysis of worldwide data found that for every 50 women who use estrogen plus daily progesterone for five years starting at age 50, one additional woman will develop breast cancer over the following 20 years. For estrogen-only therapy, that number drops to one additional case per 200 women. Ten years of use roughly doubles those figures.
The risk is real but modest, especially for estrogen-only users. It also needs to be weighed against the benefits: relief from symptoms that can seriously erode quality of life, protection against bone fractures, and potential cardiovascular benefits when therapy is started in the right window. For most healthy women in their 50s, the balance favors treatment, particularly when using the lowest effective dose for the shortest necessary duration.
Patches and Gels vs. Pills
How estrogen enters your body changes its safety profile. Oral estrogen (pills) passes through the liver before reaching the rest of your body, and this “first pass” effect increases the production of clotting factors. Transdermal estrogen, delivered through patches, gels, or sprays, bypasses the liver entirely and reaches the bloodstream at lower, steadier doses that more closely mimic premenopausal hormone levels.
The difference in blood clot risk is striking. Multiple studies have found that oral estrogen increases the risk of venous thromboembolism (blood clots in the legs or lungs) by 1.5 to 4 times, while transdermal estrogen shows no significant increase at all. One large case-control study found oral estrogen carried a relative risk of 3.5 for clots, compared to 0.9 for transdermal, meaning patch users had no elevated risk whatsoever. This advantage holds even for women who carry genetic clotting risk factors.
For this reason, transdermal delivery is generally considered the preferred route, especially for women who are overweight, have high blood pressure, elevated triglycerides, or any history of clotting problems. Patches and gels also allow for lower effective doses because less hormone is lost during absorption.
Bioidentical vs. Compounded Hormones
The term “bioidentical” simply means the hormone molecule is chemically identical to what your body naturally produces. Many FDA-approved products are bioidentical, including estradiol patches and micronized progesterone capsules. These have undergone rigorous testing for safety, dosing consistency, and efficacy.
Compounded bioidentical hormones are a different matter. These are custom-mixed by specialty pharmacies and are not evaluated or approved by the FDA. They lack standardized labeling and safety warnings. A National Academies committee reviewing the evidence was unable to find research that could support conclusions about the safety of compounded formulations for breast cancer or other risks. The absence of safety data is not the same as evidence of safety.
Some clinics market compounded pellets, creams, or troches as superior or “more natural” than FDA-approved options. There is no clinical evidence supporting this claim. FDA-approved bioidentical hormones offer the same molecular structure with the added assurance of consistent dosing, quality control, and safety monitoring. Unless you have a specific allergy to an inactive ingredient in approved products, compounded hormones don’t offer a demonstrated advantage.
Bone Protection From Hormone Therapy
Hormone therapy is one of the most effective ways to prevent the rapid bone loss that begins at menopause. A meta-analysis of 22 clinical trials found that hormone therapy reduced the risk of nonvertebral fractures by 27% overall, with hip and wrist fracture risk dropping by 40%. These are significant numbers, particularly for women with a family history of osteoporosis or who have other risk factors for fractures.
Current guidelines consider hormone therapy appropriate for preventing bone loss in women under 60 or within 10 years of menopause. It is not recommended as a first-line treatment solely for fracture prevention in women over 60, where other bone-specific medications may be more appropriate.
Testosterone Therapy for Men
Hormone replacement isn’t only a menopause conversation. Men with clinically low testosterone, defined as a total testosterone level below 300 ng/dL combined with symptoms, may benefit from testosterone replacement therapy. Symptoms of low testosterone include reduced sex drive, erectile difficulty, fatigue, loss of muscle mass, increased body fat, depressed mood, and anemia.
Treatment can improve erectile function, sex drive, bone mineral density, lean body mass, depressive symptoms, and anemia. It increases muscle and reduces fat, though it doesn’t typically change overall body weight. The American Urological Association emphasizes that low blood levels alone aren’t enough for a diagnosis. You need both the lab result and the symptoms to warrant treatment.
What “Best” Actually Looks Like
For most women experiencing moderate to severe menopause symptoms, the best-supported approach based on current evidence is an FDA-approved transdermal estradiol product (patch, gel, or spray) combined with micronized progesterone if you still have your uterus. This combination offers effective symptom relief with the lowest demonstrated risks for blood clots and breast cancer among the available options. Starting within 10 years of menopause, at the lowest dose that controls your symptoms, maximizes the benefit-to-risk ratio.
For vaginal dryness and urinary symptoms without significant hot flashes, low-dose vaginal estrogen (creams, rings, or tablets) treats the problem locally with minimal absorption into the bloodstream. For men, FDA-approved testosterone delivered via gels, patches, or injections, prescribed after proper blood testing and symptom evaluation, represents the evidence-based standard. In every case, the “best” therapy is the one matched to your specific symptoms, risk factors, and health goals.